What specific patient demographics were tested with sapropterin?

What age groups were studied in the clinical trials?

Sapropterin was tested in children, adolescents, and adults with phenylketonuria. In one trial, patients ranged from 8 to 45 years old. In another, patients aged 4 to 12 years were evaluated.

Why were younger children excluded from some studies?

The youngest patients tested in some trials were 4 years old. Data for infants and toddlers under 4 years old are limited, so doctors must use professional judgment when considering sapropterin for that group.

What ethnic groups or geographic regions were represented?

Trial participants came from the United States, Canada, and Europe. Specific ethnic breakdowns are not publicly detailed in the summary reports.

How was the response to sapropterin measured?

Researchers tracked blood phenylalanine levels and tyrosine levels after 8 days of treatment. The trials focused on patients whose blood phenylalanine levels dropped at least 20% or 30% in response to the drug.

What happened in the extension studies?

Extension trials allowed patients who had responded to continue taking sapropterin for months or years. The studies tracked long-term safety and stability of blood phenylalanine levels.